Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
Ansell SM.
Am J Hematol. 2024 Dec;99(12):2367-2378. doi: 10.1002/ajh.27470. Epub 2024 Sep 6.
Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY, Mohty M, Chim CS.
Hematology. 2015 Mar;20(2):61-71. doi: 10.1179/1607845414Y.0000000175. Epub 2014 Jul 3.
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM.
Leuk Lymphoma. 2022 Jan;63(1):231-234. doi: 10.1080/10428194.2021.1975190. Epub 2021 Sep 6.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM.
Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
Non-myeloablative transplantation.
Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA.
Hematology Am Soc Hematol Educ Program. 2002:392-421. doi: 10.1182/asheducation-2002.1.392.
Non-myeloablative hematopoietic stem cell transplantation.
Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R.
Transfus Clin Biol. 2001 Jun;8(3):231-4. doi: 10.1016/s1246-7820(01)00137-9.
Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis.
Yoon JH, Park SS, Min GJ, Park S, Lee SE, Cho BS, Kim YJ, Lee S, Kim HJ, Min CK, Cho SG, Lee JW, Eom KS.
Ther Adv Hematol. 2020 Jun 30;11:2040620720932038. doi: 10.1177/2040620720932038. eCollection 2020.
Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK, Ostrowski SR, Jørgensen NR, Schierbeck F, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Sengeløv H.
Transpl Immunol. 2022 Oct;74:101650. doi: 10.1016/j.trim.2022.101650. Epub 2022 Jun 16.
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
Atilla E, Ataca Atilla P, Demirer T.
Balkan Med J. 2017 Jan;34(1):1-9. doi: 10.4274/balkanmedj.2017.0055. Epub 2017 Jan 5.
Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
Cao XY, Chen JQ, Wang H, Ma W, Liu WW, Zhang FF, Xue S, Dong L, Liu T, Zhao XZ, Liu CC, Xu X, He Y, Wang L, Wang JL.
Ann Med. 2023 Dec;55(1):388-400. doi: 10.1080/07853890.2022.2164610.
